Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated

NEKTAR THERAPEUTICS

2023-Q3 EPS reported -$1.23 revenue$66,237,000

Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).
Revenue $24.1M, slightly up from $23.6M y/y; cash $372.7M, down from $505.0M at year-end.
Initiated Phase 2b study of rezpegaldesleukin in atopic dermatitis (Oct 2023); Phase 2b alopecia areata to start early 2024.
Clinical collaboration with CBMG to evaluate NKTR-255 in combination with TIL therapy in NSCLC.
R&D expense reduced to $24.1M (Q3) due to wind-down of bempegaldesleukin program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

NEKTAR THERAPEUTICS reported the third quarter ended September 30, 2023 results: revenue $24.1 million, net income Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share, EPS $0.24 basic and diluted loss per share.

Period: the third quarter ended September 30, 2023
Revenue: $24.1 million
Net income: Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share
EPS: $0.24 basic and diluted loss per share
Result: reported results

Exact text from the filing

least $320 million in cash and investments which provides us with a cash runway into the middle of 2026.” Summary of Financial Results Revenue in the third quarter of 2023 was $24.1 million as compared to $23.6 million in the third quarter of 2022. Revenue for the first nine months of 2023 was $66.2 million as compared to $70.0 million in the first nine months of

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-084317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.